Remove tag data-science
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science? The first clinic; trials were everything but encouraging but so much depend ended on this drug’s approval that Biogen returned and recited the data.

Drugs 187
article thumbnail

Grand Rounds Ethics and Regulatory Series November 11, 2022: Data Sharing and Pragmatic Clinical Trials: Law & Ethics Amidst a Changing Policy Landscape (Stephanie Morain, PhD, MPH; Kayte Spector-Bagdady, JD, MBioethics)

Rethinking Clinical Trials

Associate Director, Center for Bioethics & Social Sciences in Medicine. Ethics, Data Sharing, Pragmatic Clinical Trials. For PCTs, data volume is potentially larger, data may be “about” those beyond patient-subjects (i.e. Assistant Professor of Obstetrics & Gynecology. University of Michigan Medical School.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds February 23, 2024: Virtual Vigilance: Monitoring of Decentralized Clinical Trials (Adrian Hernandez, MD; Christopher J. Lindsell, PhD)

Rethinking Clinical Trials

But there are concerns to developing DCTs including lack of standardization and validation, regulatory and ethical uncertainties, engagement vs. coercion, data security and privacy issues, technological literacy and access, resistance to change and adoption, and lack of “safe” sharing. from 2021 to 2026.

article thumbnail

Grand Rounds January 26, 2024: Advancing the Safe, Effective and Equitable Use of AI in Healthcare (Mark Sendak, MD, MPP; Suresh Balu, MD, MBA)

Rethinking Clinical Trials

DIHI approaches this work through four pillars of innovation: implementation and health delivery science, health technology innovation, leadership and workforce development, and best practices development and dissemination. – How do you get reliable information and data for care that is received outside of Duke?

article thumbnail

Grand Rounds October 13, 2023: Incorporating Social Determinants of Health Into PCORnet (Keith Marsolo, PhD)

Rethinking Clinical Trials

Speaker Keith Marsolo, PhD Associate Professor Department of Population Health Sciences Duke University School of Medicine Slides Keywords PCORnet, Common Data Model, EHR, Social Determinants of Health Key Points There are many different definitions of social determinants of health. For example, consider food security.

article thumbnail

Grand Rounds July 28, 2023: How Can Researchers Fight Misinformation About Medicine? (Carl T. Bergstrom, PhD)

Rethinking Clinical Trials

Design stand-alone data visualizations because one thing that happens in a social media world is that the graphs and visualizations very quickly escape their containers. A paper is posted, it has a data figure, model or schematic, and it gets excerpted in the media or on individual’s social media feeds and the context is left behind.

Medicine 130
article thumbnail

Grand Rounds August 4, 2023: AI & ML: Want to Play a Game? (Eric Perakslis, PhD)

Rethinking Clinical Trials

” The key to quality of AI and utilizing AI in a beneficial way relates to the quality of the data. It’s important for organizations to recognize this and upgrade their data in order to these technologies more effectively and efficiently. The key is to have a deep understanding and control over the data being used.